Recursion Pharmaceuticals (RXRX) Margins & Profitability 2021-2026

Gross, EBITDA, operating, and net margin trends

Margins

Profit margins across the income statement

Gross Margin: -49.8%
EBITDA Margin: -1522.8%
Op. Margin: -1759.7%
Net Margin: -1708.0%

Op. margin of -1759.7% is down 842.9% YoY — costs are rising relative to revenue. Net margin at -1708.0% and gross margin of -49.8% show how much of each revenue dollar survives to profit.

Gross Margin (%)

Revenue left after direct cost of goods sold

EBITDA Margin (%)

Operating profitability independent of capital structure

Operating & Net Margins (%)

How much of each dollar becomes profit